Related Experiment Video

Updated: Dec 19, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

945

Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?

Lucia Musacchio1, Serena Maria Boccia1, Giuseppe Caruso1

  • 1Department of Maternal and Child Health and Urological Sciences, University of Rome "Sapienza", Policlinico "Umberto I", 00161 Rome, Italy.

Journal of Clinical Medicine
|June 7, 2020
PubMed

Insights

Immune checkpoint inhibitors, like pembrolizumab, offer new hope for advanced endometrial cancer. Ongoing trials explore combining these therapies with chemotherapy and radiotherapy for better outcomes.

Area of Science:

  • Oncology
  • Immunotherapy
  • Cancer Research

Background:

  • Endometrial cancer often presents early with good prognosis, but advanced/recurrent stages have poor outcomes with standard chemotherapy.
  • Tumor immune escape, mediated by programmed death-ligand 1 (PD-L1) upregulation, is a key challenge in refractory endometrial cancer.
  • Advances in understanding PD-L1 have spurred interest in immune checkpoint inhibitors (ICIs) for various solid tumors, including endometrial cancer.

Purpose of the Study:

  • To review the efficacy and safety of ICIs in endometrial cancer treatment.
  • To highlight the approval of pembrolizumab (anti-PD-1) for advanced disease.
  • To discuss future directions involving combination therapies and biomarker discovery.

Main Methods:

  • Review of clinical trials investigating ICIs in endometrial cancer.
  • Analysis of the role of PD-L1 in tumor immune escape.
  • Exploration of ongoing trials combining ICIs with chemotherapy, radiotherapy, and targeted therapies.

Main Results:

  • Immune checkpoint inhibitors show promise for advanced and recurrent endometrial cancer.
  • Pembrolizumab (anti-PD-1) is approved for selected unresectable or metastatic endometrial cancer patients.
  • Combination strategies are under investigation to enhance treatment efficacy.

Conclusions:

  • ICIs represent a significant advancement for refractory endometrial cancer.
  • Combination therapies hold potential for future treatment paradigms.
  • Further research is needed to identify biomarkers predicting immunotherapy response.
Keywords:
endometrial cancerimmune checkpoint inhibitorstargeted therapy

More Related Videos

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells07:46

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Published on: October 13, 2023

1.7K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
867